no splenomegaly or hepatomegaly. Histopathological analysis of an excised axillary lymph node showed NHL of follicular large cell type (intermediate grade, Working Poor prognosis malignant lymphoma is often treated with autologous bone marrow transplantation. Relapse Formulation). This was confirmed by two experienced pathologists. Computed tomography(CT) scans of chest and after transplantation is usually associated with disease progression and resistance to further therapy. We abdomen showed massive paraaortic and paracaval lymphadenopathy, and bone marrow biopsy revealed extensive present a case in which a 50-year-old patient relapsed with multiple pulmonary metastases shortly after perimarrow involvement by lymphoma (stage 4B). Eight cycles of combination chemotherapy with cyclophosphamide pheral blood stem cell transplantation. Remarkably, this relapse remitted spontaneously. This may provide (750 mg/m 2 ), doxorubicin (50 mg/m 2 ), vincristine (1.4 mg/m 2 ) and prednisolone (100 mg/day ϫ 5) (CHOP valuable insights into tumour cell biology and mechanisms by which stem cell mobilisation may alter this.
2
) was subsequently carried out. This resulted in a poor stem cell yield (CFU-GM 6.8 ϫ 10 4 /kg). A further mobilisation with cyclophosphamide 7 g/m 2 A significant number of patients with non-Hodgkin's lymresulted in an improved stem cell yield (CFU-GM 47 ϫ phoma (NHL) are not cured despite use of aggressive 10 4 /kg). No microscopic evidence of circulating lymphoma chemotherapy. High-dose chemotherapy with bone marrow cells was present. PCR analysis for immunoglobulin gene rescue has been employed in an attempt to induce cure in rearrangement did not detect clonal cells in the mobilised some of these patients.
1 Peripheral blood stem cell transspecimen. plantation (PBSCT) produces rapid haemopoietic reconstiAfter conditioning with cyclophosphamide (300 mg/m 2 ), tution 2 and is being increasingly used in the treatment of carmustine (300 mg/m 2 ), etoposide (100 mg/m 2 ) and melhaematological and non-haematological malignancies. One phalan (160 mg/m 2 ) the stem cells were reinfused. Apart of the major concerns in PBSCT is the collection and subfrom culture negative fever requiring antibiotics, recovery sequent reinfusion of viable tumour cells which may conwas uncomplicated. Neutrophil engraftment (count Ͼ0.5 ϫ tribute to subsequent tumour relapse. 10 9 /l) was rapid, occurring on day 11 but platelet recovery We present the case of a patient who underwent PBSCT (count Ͼ50 ϫ 10 9 /l) took 69 days. Bone marrow biopsy for resistant NHL. Complete remission was achieved but on day 28 showed early trilineage engraftment and no evisubsequently relapse occurred. Remarkably the relapsed dence of lymphoma. Repeat CT scans revealed resolution tumour spontaneously regressed, which poses a number of of paraaortic lymphadenopathy and no other disease. questions about the origins of the relapse.
Dyspnoea developed 2 months post-transplant. Chest X-ray (CXR) showed bilateral interstitial opacities with CT scan showing patchy alveolar opacities. A transbronchial biopsy Case report showed focal granulomatous inflammation and active interstitial pneumonitis with early focal fibrosis. This pneumo-A 50-year-old female presented with a 6 month history of nitis was attributed to carmustine-related pulmonary toxiabdominal pain and swelling with associated profuse night city and treated with a 6 week course of prednisolone. This sweats. Examination showed lymphadenopathy of the cerresulted in clinical and radiological improvement. vical, axillary and inguinal regions bilaterally. There was At day 161 multiple pulmonary opacities were noted on CXR and a subsequent CT scan showed bilateral pulmonary nodules (Figure 1 ). An open lung biopsy of one of these phoma. Over the following 3 months these deposits con- cate the lymphoma. Potential causes of relapse are failure to eradicate disease in the patient or infusion of viable tinued to enlarge. The patient was asymptomatic and declined further therapy. Subsequently the nodules were tumour cells which may seed new sites, or a combination of both of these processes. In fact the majority of patients noted to decrease in size and eventually disappear. Repeat CXR and CT scan on day 518 showed no evidence of relapse at sites of prior disease. 3 This patient had never had pulmonary disease. In addition, the unique vascular supply pulmonary disease (Figure 2) .
Following this complete remission the patient developed of the lungs means that all infused stem cells travel through the pulmonary vasculature. The multifocal pattern of disfurther pulmonary disease but in different sites. On day 706 a right hilar mass was noted on CXR. A bronchoscopy ease recurrence in this patient is similar to that seen in haematogenous spread although there was no evidence of disshowed minor extrinsic compression and a transbronchial biopsy showed an atypical infiltrate only. This opacity ease elsewhere at that time. It is therefore likely that relapse in this patient was due to infusion of viable tumour cells, increased in size slowly and further lesions developed throughout the right lung field. By day 1378 the mass filled even though we could not detect them by molecular methods. In our institution we have performed 49 autolothe mid and lower zones of the right lung field and relapsed lymphoma was confirmed on biopsy. Chemotherapy was gous transplants for poor prognosis NHL between 1989 and 1996. Relapse following transplantation has occurred in 28 commenced which resulted in an initial response but this was followed by regrowth of tumour. The patient subcases but no others have had a pattern of relapse as seen in this case. A report by Rossetti et al 4 describes the develsequently died on day 1562. opment of pulmonary lymphoma in a case of large cell immunoblastic lymphoma early after autologous transplantation. Their patient had previously not had pulmonary disDiscussion ease and the pattern of relapse was consistent with reinfusion of lymphoma cells. Furthermore, retrospective Autologous transplantation in lymphoma relies on supralethal doses of chemotherapy and/or radiotherapy to eradianalysis of 64 cases which had either open lung biopsy or necropsy following autologous bone marrow transplanThe case report highlights the possibility of infusing tumour cells by autologous stem cell rescue but also sugtation for lymphoma in their institution only identified pulmonary malignancy in patients who had prior pulmonary gests that mobilised tumour cells may be different in their self-renewal or adhesive properties. Understanding of tumour. Hence pulmonary recurrence due to reinfusion of lymphoma cells appears to be a rare event. This is despite mobilisation and tumour phenotypes needs to increase so that we can better plan future therapies, including purging the relatively high incidence of detectable lymphoma cells in PBSC collections 5, 6 and therefore specific mechanisms methods, in malignant lymphoma. may be responsible for the pulmonary relapse.
A further fascinating aspect of this case is the spontaneous regression of the tumour masses. This may be due to a number of possibilities. The infused tumour cells may References have been terminally committed progenitor cells with limited self-renewal potential. Consequently they retain the has recently been shown that infused malignant cells con- 1987; 11: 1115-1117. tribute to relapse in acute myeloid leukaemia 10 but whether
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